SecBot SecBot
SECBOTREPLAY Home › Report › OLMA

OLMA · Olema Oncology's Q2 2026 net loss widened to $63.2M (vs $43.8M a year…

Olema Oncology · PRESS-RELEASE filed Aug 10, 2026 at 16:01 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Aug 10, 2026 at 16:01 ET

Olema Oncology's Q2 2026 net loss widened to $63.2M (vs $43.8M a year ago) on higher R&D and G&A spending, but cash of $461.1M is ample to fund operations. The key catalyst is the completion of enrollment in the Phase 3 OPERA-01 trial, with top-line data now expected in Q1 2027, a de-risking milestone that brings the company closer to potential commercial launch. The Bayer collaboration for OP-3136 in prostate cancer also adds pipeline optionality, though the stock remains pre-revenue and binary on clinical outcomes.

  • Completed enrollment in pivotal Phase 3 OPERA-01 trial; top-line data expected Q1 2027
  • Cash, cash equivalents, and marketable securities: $461.1 million as of June 30, 2026
  • Q2 2026 net loss: $63.2 million, compared to $43.8 million in Q2 2025
  • GAAP R&D expenses: $57.8 million (vs $43.9 million in Q2 2025)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access